Research Project

Project Title:	Phase 3, randomized, blinded, multicentre, placebo-controlled study to evaluate the efficacy and safety of Inebilizumab in IgG4-related disease (MITIGATE).
Project Type:	Clinical Trial, Enrolment ongoing
Disease group(s):	Immune glomerulopathies
Project Summary:	Phase 3, randomized, blinded, multicentre, placebo-controlled study to evaluate the efficacy and safety of Inebilizumab in IgG4-related disease (MITIGATE).
Lead principal investigator(s):	Dario Roccatello, Turin
Project Period:	10/2020 - 12/2060
Sponsors:	Industry
ClinicalTrials.gov:	NCT04540497